News Flash 8.2017 – Having a Baby after Breast Cancer Diagnosis
Findings from a retrospective study recently published confirm that pregnancy after breast cancer can be considered safe, since it does not raise the risk of recurrence and/or death. The study enrolled 1,207 young women diagnosed with early stage breast cancer who were treated in medical centers throughout Europe.Approximately one third of the women included in […]
News Flash 5.2017 – Trends and Innovations in the Field of Oncology, 2017
According to the WHO (World Health Organization) data, the absolute number of new cancer patients diagnosed annually all over the world, is going to increase by about 50% over the next two decades. However, it is important to note that when specifically referring to developed countries (e.g. the USA and Western Europe), this expected increase can be […]
News Flash 7.2016 – Research Results (UpToDate July 2016)
*IVF and risk of breast cancerIn a study of over 19,000 women undergoing IVF treatment between 1983 and 1995 and followed for a median of 21 years, the risk of breast cancer was similar to that of the general population.(However, it is a bit difficult to generalize these data among women undergoing contemporary IVF treatment, since […]
News Flash 10.2015
The FDA has expanded the approved use of Keytruda (Pembrolizumab) to also treat patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed after receiving the standard treatments. Nevertheless, these patients will first have to undergo a specific laboratory test in order to identify those who may benefit from the new therapy. In […]
News Flash 9.2015
Currently approved antiemetic drugs (i.e. drugs for the treatment of nausea and vomiting), generally target the acute phase of nausea and vomiting (i.e. nausea and vomiting that occur in the first 24 hours after the start of chemotherapy). Yet, many patients also experience delayed nausea and vomiting that occur from 24 to 120 hours or […]
News Flash 4.2015
In March 2015, the FDA granted approval for Nivolumab (Opdivo) for the treatment of patients with advanced squamous non-small cell lung cancer that has progressed after treatment with chemotherapy. Nivolumab works by enhancing the ability of the immune system to fight and destroy cancer cells (see:” Keytruda – a new anti-cancer drug”). Nivolumab is already […]
News Flash 3.2015
In February 2015, the FDA granted accelerated approval for a new drug, Palbociclib (Ibrance), for the treatment of post-menopausal women with advanced breast cancer whose tumors are hormone receptor positive and HER-2 negative.Defined as a breakthrough therapy among these patients, Palbociclib, given as tablets, signals a new strategy for arresting cell tumor growth. In a […]
Keytruda (Pembrolizumab) – a new anti-cancer drug approved as state-subsidized in Israel, 2015
Keytruda is a new anti-cancer drug. It works through an innovative mechanism of action that neutralizes the ability of cancer cells to fight and paralyze the immune system. How?Our immune system is made up of several types of cells. The purpose of these cells is to protect the body and its biological systems (e.g. the urinary system, […]
Recent Cancer Data; Incidence and Mortality
According to recent data from the USA, the lifetime probability of being diagnosed with cancer is about 44% for men and about 38% for women. In other words, almost one in two men and more than one in three women will develop cancer during their lifetime. Yet, it is important to note that during the last […]